• April 14, 2009
  • North America

Quinnova Pharmaceuticals, Inc. Receives FDA Clearance on Neosalus™ Cream

NEWTOWN, PA-April 14th, 2009 – Quinnova Pharmaceuticals, Inc. announced that it has received FDA clearance on the company’s new product NEOSALUS CREAM, a line extension to the previously launched NEOSALUS FOAM, the first non-steroidal anti-inflammatory prescription topical foam product for the treatment of various types of dermatoses including atopic dermatitis and hand eczema. Both NEOSALUS CREAM and NEOSALUS FOAM are uniquely formulated with Quinnova’s patented Proderm Technology TM, which provides skin barrier repair, protection, and moisturization.

“To treat recalcitrant skin conditions such as atopic dermatitis and hand eczema, a comprehensive and long term solution is required to address the underlying issue of a compromised skin barrier while reducing inflammation. Additionally, to meet patient preferences and increase their compliance, a range of vehicles containing the same base formulation targeted at treating different disease states and locations of the body is desirable for both patient satisfaction and treatment outcome. NEOSALUS CREAM, in addition to NEOSALUS FOAM, increases the product selection choice of Quinnova’s Neosalus brand for both the patient and the Healthcare Provider”, said Dr. Christopher N. Hensby, Senior Vice President of Quinnova Pharmaceuticals.

Whether as cream or foam, NEOSALUS helps to restore a dysfunctional skin barrier by replenishing the lost physiological lipids, thereby decreasing trans-epidermal water loss (TEWL). Furthermore, Neosalus functions as a protectant to reduce the penetration of irritants from further exacerbating the itch and scratch cycle. Finally, Neosalus has anti-inflammatory ability that helps to reduce the frequency and severity of flare-ups, thus making it a steroid sparing and complementary treatment to other concomitant treatments.

In addition to the therapeutic benefits of NEOSALUS CREAM and NEOSALUS FOAM, patients will likely appreciate the cosmetic elegance of Proderm Technology TM. Unlike some creams and lotions which have a tendency to leave the skin feeling greasy after application, Neosalus, a water-lipid based formulation, absorbs quickly, spreads easily, and is non-greasy. Patients can resume their work and daily activities immediately after applying Neosalus, thus enhancing compliance and maximizing treatment results.

Quinnova Pharmaceuticals’ sales force calls on dermatologists and podiatrists across the United States.

About Quinnova Pharmaceuticals, Inc.
Quinnova Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of prescription drug products based on innovative topical drug delivery platforms. For more information, please visit www.quinnova.com.


Jana Wang
Quinnova Pharmaceuticals, Inc.
411 South State St. 3rd Floor
Newtown, PA 18940
(215) 550-2023